Gufic Biosciences Ltd
Q1 FY27, unaudited
- Revenue
- ₹260.82 Cr
- Profit after tax
- ₹22.46 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 260.82 | +14.94% | 940.48 |
| Other income | 0.46 | −48.84% | 2.58 |
| Total income | 261.28 | +14.69% | 943.06 |
| Employee benefit expense | 41.80 | +16.14% | 151.68 |
| Finance costs | 9.32 | +0.92% | 36.61 |
| Depreciation & amortisation | 7.71 | −0.17% | 30.83 |
| Total expenses | 231.11 | +9.26% | 857.57 |
| Profit before tax | 30.16 | +85.30% | 85.49 |
| Tax expense | 7.70 | +83.21% | 22.34 |
| Profit after tax | 22.46 | +86.03% | 63.15 |
| Total comprehensive income | 22.46 | +86.03% | 63.65 |
| Earnings per share, basic | ₹2.24 | ₹6.30 |
|---|---|---|
| Earnings per share, diluted | ₹2.24 | ₹6.30 |
Earnings call
Q4 FY26Gufic Biosciences reported Q4 FY26 revenue of around INR252 crores, its strongest quarter ever, with EBITDA margin expanding to 17.73% from 13.17% a year earlier and PAT more than doubling year-over-year. Full year FY26 revenue was INR940.50 crores versus INR820 crores in FY25, with EBITDA of INR152.9 crores and PAT of INR63.2 crores. Management attributed the quarterly improvement to the Indore facility reaching EBITDA breakeven at 30% capacity utilization, a working capital reset in the Critical Care cluster, and growth in the women's health and aesthetics platforms.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Filings
12 shown · 40 published by the exchange
21 Aug 2026
Transcript18 Aug 2026
Filing17 Aug 2026
15 Aug 2026
Filing14 Aug 2026
Presentation14 Aug 2026
Filing14 Aug 2026
14 Aug 2026
13 Aug 2026
Filing12 Aug 2026
12 Aug 2026
12 Aug 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 21 Aug 2026.